missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ PEAR1 Polyclonal Antibody

Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA583262
This item is not returnable.
View return policy
Description
Immunogen sequence: PSDPNTCSFW ESFTTTTKES HSRPFSLLPS EPCERPWEGP HTCPQPTVVY RTVYRQVVKT DHRQRLQCCH GFYES Highest antigen sequence indentity to the following orthologs: Mouse - 80%, Rat - 79%.
Platelet endothelial aggregation receptor 1 (PEAR1) is a platelet receptor that signals upon the formation of platelet-platelet contacts independent of platelet activation and secondary to platelet aggregation. Upon platelet aggregation stimulated by physiological agonists, PEAR1 becomes tyrosine- and serine-phosphorylated; the tyrosine phosphorylation can be inhibited by eptifibatide, an aIIbbeta3 antagonist that also inhibits platelet aggregation. Recent studies have indicated that genetic variations in PEAR1, may be associated with enhanced agonist-induced platelet aggregation.
Specifications
| PEAR1 | |
| Polyclonal | |
| Unconjugated | |
| PEAR1 | |
| 3110045G13Rik; hPEAR1; Jagged and Delta protein; Jedi; Jedi-1; MEGF12; mPEAR1; Multiple EGF-like domains protein 12; multiple EGF-like-domains 12; multiple epidermal growth factor-like domains protein 12; Pear1; Platelet endothelial aggregation receptor 1; protein Jedi; RGD1305653; RP11-107D16.3 | |
| Rabbit | |
| Antigen affinity chromatography | |
| RUO | |
| 375033 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
| Immunohistochemistry (Paraffin), Immunocytochemistry | |
| 0.1 mg/mL | |
| PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
| Q5VY43 | |
| PEAR1 | |
| Recombinant protein corresponding to Human PEAR1. Recombinant protein control fragment (Product #RP-95727). | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction